WO1988006184A1

WO1988006184A1 - Viral antigen, process for its production, and application in diagnosis and therapy (vaccine)

Info

Publication number: WO1988006184A1
Application number: PCT/EP1988/000123
Authority: WO
Inventors: Renate Seelig; Hans Peter Seelig; Jean Burckhardt
Original assignee: Renate Seelig; Hans Peter Seelig; Jean Burckhardt
Priority date: 1987-02-20
Filing date: 1988-02-19
Publication date: 1988-08-25
Also published as: AU1347688A; FI884823A; CN88101839A; FI884823A0; JPH01502956A; AU620801B2; EP0279460A1; DE3744242A1; KR890700662A

Abstract

A DNA of approximately 5 KB, associated with non-A,non-B hepatitis, process for the production of same according to known methods, and application of said DNA or of fragments of same in the diagnosis of non-A,non-B hepatitis, as well as in the synthesis of proteins for the generation of immunological reagents to detect non-A,non-B hepatitis or to produce vaccines. The DNA and fragments of same can be cloned and also be introduced into appropriate vectors, in order to obtain viral expression products.

Description

Virus antigen, method for its production and use in diagnosis and therapy (vaccine)

Non-A, Non-B hepatitis diseases have been extensively and extensively described in the literature. However, the difficulties in detecting the NANBH virus and detecting the disease are also known.

Particles have now been isolated from the stool of non-A, non-B hepatitis patients and characterized in terms of their molecular weight and nature, and a detection method for the presence of such particles has been found and the detection of these particles

Diagnosis of the presence of non-A, non-B hepatitis applied to patients with liver disease.

DNA was isolated from the particles isolated from the stool and cloned by conventional methods. The cloned DNA strands obtained in this way were used to detect the presence of homologous or very similar DNA in the stool, serum, liver tissue and body fluids of liver-sick patients, in whom non-A, non-B hepatitis was diagnosed with sufficient probability can be.

The invention thus relates in summary to the isolation of non-A, non-B hepatitis-associated particles, their DNA and the cloning of DNA and the use of both these particles and the DNA clones obtained to limit living diseases to the presence of a non -A, non-B hepatitis. Further aspects of the invention lie in the development of extended detection methods and finally also vaccines on the basis of the antibodies to be obtained and by synthesis of synthetic peptides with the sequence of the particles which corresponds to these virus proteins and which can be predicted from the sequence of the cloned DNA.

A substance was isolated from the stool samples of non-A, non-B hepatitis patients with significantly different ge found in the stool of such non-A-non-B hepatitis patients, on the other hand in healthy, and in patients with liver diseases of other origins to a significantly lesser extent. A method for detecting this substance was developed in which polystyrene beads with diluted serum of non-A Non-B hepatitis convalescent can be coated. The washed beads are then incubated with a 10% stool suspension of a subject to be examined, any non-A-non-B-hepatitis-associated substance binding to the antibodies against this substance contained in the convalescent serum and bound to the polystyrene balls and is immobilized like this. The binding of the non-A, non-B hepatitis-associated particles can be demonstrated by binding human IgG, in turn, from convalescent serum from non-A, non-B hepatitis patients which is radioactively labeled with iodine 125. If the non-A, non-B hepatitis-associated substance is present in the subject's stool, radioactive immunoglobulin is bound to it and the corresponding signal is used for detection.

When using this detection method for the hepatitis non-A non-B-associated substance in large groups of patients with liver diseases of different origins, it was found that this substance was highly significant in patients with confirmed hepatitis non-A, non-B im

Stool is detectable (see Table 1). In patients with other liver diseases in whom non-A, non-B hepatitis is rather unlikely, but some of whose clinical picture may resemble acute or expired non-A, non-B hepatitis, especially in patients with In contrast, acute non-expired hepatitis A or B only found the non-A, non-BHepatitis-associated substance in very few cases (see Tables 2 and 3). From this it follows that the presence of this substance is a clear indication of the etiology of an initially: unbe known, inflammatory liver disease, and that the detection of this substance can therefore provide an examination of high diagnostic value to detect or rule out the presence of non-A, non-B hepatitis.

The substance associated with the non-A, non-B thus has a high affinity for human immunoglobulins and fibronectin and its non-collagen-binding cleavage products. The binding to Fab-2Bbruch from the IgG of healthy and hepatitis non-A, non-B convalescent persons speaks against non-specific binding of the associated substance to the Fc part of the immunoglobulins. The high affinity for fibronectin and its non-collagen-binding cleavage products is a property that this substance has in common with antigenic proteins of other viruses (Seelig and co-workers 1983).

Treatment with organic solvents (chloroform, ether) and with heat (70 ° C, 10 min.) Does not destroy the binding affinity of the non-A, non-B associated substance. While digestion with chymotrypsin, trypsin, elastase and neuraminidase shows no influence on the binding properties of the substance, digestion with papain leads to a complete and rapid loss of binding affinity.

After centrifugation at 150,000 g, 2 hours, it can be detected in the sediment and, after a 72-hour run time, is established at a density of 1.3 (1.29 - 1.32) g / ml cesium chloride. After separation of the fraction banding at 1.30 g / ml of cesium chloride by means of gradient polyacrylamide gel electrophoresis, several bands of different molecular weights are shown in the silver staining. After transfer to nitrocelulose, bands can be displayed in the Western blot with radioactively labeled IgG and Fab-2 fragments from non-A, non-B hepatitis patients and healthy volunteers, which do not occur when healthy controls are extracted. A total of 4 bands are shown, two good visible main band with an estimated molecular weight of approx. 64,000 and 56,000 as well as two weaker bands with an estimated molecular weight of 51,000 and 43. 000. The bands with Fab-2 fragments are weaker and show a higher background. The separation of raw stool concentrates without cesium chloride purification according to SDS-Page and Blσtting showed the two main bands with an approximate molecular weight around 60,000 in positive stools.

Further analysis of the non-A, non-B hepatitis-associated particles enabled DNA to be isolated and cloned into fragments using conventional methods. These cloned DNA fragments from the stool of non-A, non-B hepatitis patients could be used as DNA probes for the examination of stool, serum, liver tissue and body fluids as well as blood supplies and plasma derivatives of other patients with suspected non- A, non-B hepatitis can be used. The classic hybridization methods can be used to show whether there is DNA in the unknown stool whose sequence is so similar to the non-A, non-B hepatitis-associated DNA of the clones obtained that a hybridization signal is shown. With this further detection method for hepatitis non-A, non-B-associated DNA sequences, samples from test persons could then be examined for the presence of non-A, Nσn-B hepatitis-associated DNA. The results to date suggest that the non-A, non-B hepatitis-associated substance is a virus particle and that the isolated DNA sequence is a sequence of virus DNA, like the digestion method on the one hand and on the other hand show the sequence itself.

The following examples illustrate the invention.

example 1

Isolation of Non-A-Non-B Hepatiris Associated. Substance from patient pool. Buffer used: Tris-HCl, pH 7.4; 0.05 N in all working steps a) Work-up: 0.5 g stool are suspended in 10 ml buffer, centrifuged at 8.00 0 g and the supernatant collected. The residue is washed out again with 10 ml and then with 5 ml of buffer. The collected supernatants are centrifuged (30 min., 10,000 rpm) and filtered through a bacteria-tight filter (Millipore 0.22 µm). The supernatant is precipitated with PEG 6000 (final concentration 10% or 0.4 mol / l). After at least 2 and at most 12 hours, the precipitate is centrifuged off and dissolved in 10 ml of buffer. This solution comes with 10 ml

Freαn shaken out, the phases separated by centrifugation, the Freαnphase washed again with 5 ml of buffer. The precipitation with PEG and NaCl (final concentration 10% or 0.4 mol / l) is repeated. The precipitate is taken up in about 800 μl of buffer.

The solution thus obtained is digested with RNase and DNase for 1 hour at 37 ° C. (80G ul PEG precipitate in Tris-HCl buffer, pH 7.4; 0.05 M; 2,800 U RNase and 1,500 U DNase, protease-free preparations, Boehringer). Isolations that are not used to extract DNA can be performed without this step.

After digestion with DNase and RNase, the incubate is brought to a cesium chloride gradient.

b) Isolation of the non-A, non-B associated substance via a cesium chloride gradient.

The centrifuge tubes are added with 1 ml of cesium chloride solution with a density of 1.4 g / ml and covered with 3 ml of cesium chloride with a density of 1.3 g, 1.25 g and 1.2 g / ml. All cesium chloride solutions are prepared with the above-mentioned buffer, the gradient is overlaid with 800 μl stool extract, the centrifugation time is 65 - 72 hours. Temperature + 10 ° C, rpm 31,000. After the end of the runtime, the gradient is collected in the lower region (density 1.2-1.4) in fractions of approximately 200 μl, in the upper region density 1.1-1.2 larger fractions can be removed. The density of each fraction is determined by measuring the refractive index. All fractions are dialyzed against buffer and 50 μl of each fraction in NANB assay tested for non-A, non-B associating substance. The Lowry protein concentration is determined from the positive fractions.

Verification and characterization of the substance

c) Creation of a gradient page

Two solutions with different acrylamide concentrates are layered into a linear gradient using a gradient mixer. The solution with the higher AA concentration also contains 15% sucrose to prevent turbulence. Otherwise, the solutions are composed as described in LAEMMLI (1970). This also applies to the comb gel.

The dialyzed and possibly narrowed fractions of the cesium chlorideϊd gradient are mixed with 10 μl SDS, 10 μl glycerol and 5 μl beta-mercaptoethanol, 5 μl bromophenol blue per 100 μl sample and boiled in a water bath for 3 minutes. Then they are mixed with 5 μl of 0.1% pyronine and applied to the gel. Running time 3 1/2 hours, voltage 160 - 300 V, current 40 - 25 A, power 20 W.

Approximately 5 minutes before the end of the run, 5 μl of pyronine is applied once and the run is ended as soon as pyronine has passed through the comb gel. The gel is either stained with silver (WRAY and coworkers 1981) or Western blotting (TOWBIN and coworkers 1979). Blotting is carried out overnight at 0.5 A, then 1 hour at 1 A.

d) treatment of Western blots

After blotting is complete, the various strips (indicated by the pyronine markings) are cut out and molecular weight standards carried along are colored black with Amido. Sample strips are shaken for 24-72 hours in 1% gelatin PBS solution. The IgG fraction of a patient or the Fab-2 fragments of this IgG fraction are labeled with iodine 125 (chloramine T): 0.5 mCi per 100 μg protein. About 70% of the activity is incorporated. The tracer, the volume of which should correspond to approximately 2 µg of protein, is diluted in 20 ml of gelatin / PBS and the strips are incubated for 12 hours with shaking. The strips are then washed 3 times with gelatin-PBS, 2 x with PBS-Tween 0.5% and 1 x with water for 1 hour each. After the strips have dried, they are placed on a sensitive X-ray film and exposed at -70 ° C for 2-7 days. Example 2 Detection method for HNANB-associated substance in the chair

Polystyrene beads (Plasticball Company, Chicago) were treated with serum from convalescent patients with non-A, non-B hepatitis at a dilution of 1: 200 in carbonate buffer, pH 9.2, 0.01 mol / 1, 12 hours at room temperature incubated. The beads coated in this way were washed extensively with phosphate-buffered physiological saline (PBS). The stool samples were incubated in the form of a 10% stool suspension (w / v) for 2 hours at 37 ° C. with the polystyrene beads layered as above, then washed extensively with PBS containing 0.5% Tween 20 and then for 1 hour incubated with human IgG from the serum of convalescent non-A, non-B hepatitis labeled with iodine 125 at 37 ° C. After renewed, thorough washing with distilled water, the radioactivity bound to the beads was counted using a gamma counter. Stool samples in which the bound radioactivity reached three times the value of the negative control were found to be positive for the presence of the non-A, non-B hepatitis-associated substance.

Each of the attached tables 1 to 4 was created as described above and evaluated according to the specified criteria. It was found that according to Table

1 In patients with confirmed non-A, non-B hepatitis, this substance was found in a large percentage of cases that, according to Table 2, when this substance was used for this non-A, Npn-B hepatitis-associated substance a patient collectively with a variety of entirely below various liver diseases, which have nothing to do with non-A, non-B hepatitis, the substance is found in very low percentages, if at all.

Table 3 shows that a very low percentage of the non-A, non-B-associated substance is found during the examination of patient groups with hepatitis of a different origin, that is to say either hepatitis A or hepatitis B.

It should be noted that the non-A, non-3 hepatitis cases almost always have positive results, i.e. almost 30%, whereas the numbers are considerable in the case of hepatitis A, suspected hepatitis A, hepatitis B and posthepatitis B. lie lower.

The relatively high positive number for the substance in chronic hepatitis B patients suggests that it is a double infection with non-A, non-B and hepatitis s B.

Table 4 shows the following: An investigation of recipients with a blood transfusion, who in principle have to be considered as risk patients, because non-A, non-B hepatitis infection often occurs in blood infusions. It is a prospective study.

This clearly shows that, depending on the severity of the consequences of the transfusion, on the one hand nothing has happened to patients, where these substances have been excreted to a very limited extent, on the other hand in patients in whom the disease is recognizable and in to those who have overt hepatitis in over

70% of the time this substance is detectable.

Example 3: Isolation of DNA from the stool and cloning of DNA sequences and their incorporation into corresponding vectors.

Incorporation of this DNA into cloning vectors.

As described in Example 1, non-A, non-B hepatitis-associated particles were isolated from the stool of patients with non-A, non-B hepatitis and, as described there, treated with RNAs and DNAs and via a

Cesium chloride gradient cleaned and dialyzed extensively. The dialyzed fractions were examined for the presence of NANB-associated substance in the manner described above. The fraction of the density of 1.3 g / ml in the cesium chloride gradient was digested with 50 micrograms of proteinase K, 1% SDS and EDTA in a final concentration of 10 mM / l for 6 hours at 37 ° C. Proteins were extracted by extraction with 80% phenol

(Weight / volume) and chloroform removed, and then the DNA dissolved in the aqueous phase in the presence of 0.3 mol / 1 of sodium acetate with a two and a half times the volume of ethanol for 60 hours at -70 ° C. It was then centrifuged and the sediment was washed once with 70% ethanol, dried and then in TE buffer consisting of 10 mmol / l Tris, pH 3.0, and 1 mmol / l EDTA, in a volume ratio of one microliter / 5 mg of worked up stool.

15 microliters of this DNA stock solution were mixed in a total reaction volume of 50 microliters with 6 units of Klenow polymerase (DNA polymerase I, large fragment), 1 microliter of a reading of dATP, dTTP and dGTP, each in a concentration of 1 mM / l, and 5 Microliter alpha32P-d CTP (3,000 Ci / mmol, 10 mCi / ml) in the incubation buffer for Klenow polymerase according to the manufacturer's instructions (Boehringer, Mannheim) incubated for 1 hour at room temperature. Then 2.5 microliters of a 1 mmol / l dCTP solution were added and the sample was incubated for a further hour at room temperature. After inactivating the enzyme by heating at 68 ° C for 10 minutes, the reaction solution was cooled to 0 ° C. The reaction mixture was then incubated together with 2 units of T4 DNA ligase, 1 microgram of phosphorylated EcoR-I linker and 6 microliters of 10 mM ATP solution at 16 ° C. for 16 hours. The reaction mixture was then adjusted to a final concentration of 150 mmol / l NaCl and treated with 240 units of EcoR-I restriction endonuclease (80

Units / microliter) digested for 3 hours at 37 ° C. The reaction would be stopped by adding 5 microliters of 80% phenol and 1 microliter of 20% SDS. The radioactively labeled and provided with linkers was separated from salt and non-alloyed linkers via a Sepharose 4B-CL column (3 ml column volume, 25 cm length) and precipitated with 2.5 volumes of ethanol at -70 ° C. for 16 hours. The precipitated DNA was centrifuged at 14,000 g for 10 minutes and the sediment was washed with 150 microliters of 70% alcohol, dried and taken up in 10 microliters of TE buffer.

Example 4: Installation of the isolated DNA in lambda phages and transfection on bacteria.

For ligation with the vector DNA, 2 micrograms of phage lambda 1149 DNA with 2 units of EcoR-I (4 U / microliter) in a total reaction volume of 6 microliters (incubation buffer as specified by the enzyme manufacturer (Boehringer, Mannheim)) were used at 37 ° for 1 hour C. Then the enzyme was inactivated by heating for 10 minutes at 68 ° C. This solution was isolated with 3 microliters of labeled DNA, which wio described in the previous example, 1 microliter of 5 mM ATP and 1 unit of T4 DNA ligase 4 microliters of this reaction mixture were packaged in lambda phage sleeves (using a ready-to-use extract from Giga-Pack, Vector-cloning Systems), with which the Escherichia Coli strain was obtained NM 514 infected. In order to screen for the presence of built-in DNA, approximately 10 ⁵ "plaque fcrming units" were plated onto 22 x 22 cm screening plates from Nunc and incubated at 37 ° C. overnight. Phage DNA was transferred to nitrocellulose filters by contact and the contact filters thus obtained were washed with 1 microliter of the radioactive DNA stock solution described above according to Maniatis et al. (1982) hybridized, washed and autoradiographed for 6 hours at 70 ° C.

Out of 70 positive hybridization signals, 17 assigned phage colonies were placed at a density of approx. 5 plaques per cm. After plaques purification according to BENTON and DAVIS (1978), lysates were produced from the 16 positive plaques finally obtained. Several of these phages contained DNA inserts between 0.3 and about 1.5 KB in length that hybridized to a sample of the original DNA stock solution.

Example 5: Characterization of a DNA fragment of 0.45 KB and subcloning of this fragment in a plasmid PUC 19 in Escherichia coli.

The DNA fragment was removed from the phage DNA by digestion with appropriate restriction endonucleases (EcoR-I) under the conditions already described above, the fragment was then separated from the lambda phage DNA on agarose gel and the DNA band corresponding to the insert was removed cut out the gel and eluted. The insert DNA isolated in this way is then ligated exactly as described above, into vector DNA PUC 19 and then transfected to Escherichia coli strain DH 1. After selection of bacterial strains that have taken up this plasmid with the built-in hepatitis non-A, non-B DNA insert and multiply, the cultivation was then carried out and, as in T. Maniatis et al. 1982, in "Molecular Cloning, a laboratory manual ", described, processed.

The same insert was radioactively labeled and checked with Southern analysis for hybridization with the DNA starting material, DNA extractions from stools from control persons, hepatitis B virus DNA and Escherichia coli plasmid PBR 322.

Example 6: Detection of non-A, non-B-associated DNA in serum

2 - 5 ml of serum are centrifuged at 150,000 g for 2 hours. The sediment is digested in 200 μl proteinase K solution (0.5 mg / ml + 10 mmol EDTA) at 37 ° C. for 1 hour. Then 165 μl of a hot saturated sodium iodine solution (2.5 g sodium iodide / ml H ₂ O, 75 ° C.) are added to this solution (final concentration 12.5 M). This solution is heated to 90 ° C. for 10 minutes and immediately filtered through a nitrocellulose filter using a vacuum (dot blot apparatus, Schleicher + Schüll). After the filtration, the nitrocellulose film is washed 3 times with 70% ethanol and then incubated for 10 minutes at room temperature in 100 ml of acetic anhydride (100 ml of 0.1 M triethanolamine + 250 μl of acetic anhydride). After the incubation, the film is baked in a vacuum at 80 ° C for 1-2 hours. The dry film is placed in prehybridization solution and incubated for 3 hours at 65 ° C (6 x SSC, 1 x Denhardt, 0.5% SDS, 20 µg / ml heat denatured herring sperm DNA as described in: Maniatis, Molecular Cloning, 1982 ). Incubated by nick translation (see Maniatis, Molecular Cloning, 1982) with 32P-labeled sample overnight under prehybridization conditions. The nitrocellulose sheet is then washed 3 times (1) 6 x SSC, 1 x Denhardt, 0.5% SDS, 20 μg / ml herring sperm DNA, 2). 1 x SSC, 0.5% SDS, 1 x Denhardt, 3). 0.1 x SSC + 0.05% SDS). After the film has dried, it is placed on an X-ray film (Kodak X-Ornat) (autoradiography time 6 hours to 2 days at -70 ° C). For sera with a high content of HNANB viruses, the concentration of 2-5 ml serum by centrifugation can be omitted and the sera after proteinase K digestion according to the method (Seelig et al., Clinician 2/1985, page 86 ff) directly can be applied to nitrocellulose. (see example 7)

Example 7: HNANB DNA detection in serum

200 ul of serum are incubated with 75 ul of Proteinase K solution (Boehringer) (4 mg / ml) and 25 ul of 0.5 M EDTA at 37 ° C. for 1 hour. The incubate is incubated with 100 μl of 1N NaOH for 10 minutes at room temperature and neutralized with 250 μl of 2 M NH ₄ OAc. 500 ul of the batch (corresponding to 181 ul of serum) are applied to nitrocellulose (Dott-BIott apparatus Schleicher + Schüll). After neutralization again with 250 μl of 2 M NaH ₄ OAc, the filters are dried in vacuo at 80 ° C. for 45 minutes. The filters are pre-hybridized in 6 x SSC *, 0.5% SDS **, 1 x Denhardt's solution *** and 20 µl / ml heat of denatured (5 minutes, 100 ° C) herring sperm DNA at 65 ° C for 3 hours . For hybridization, which takes place overnight under prehybridization conditions, the inserts of the phage clones, which are labeled with 32P, are used (specific activity approx. 1-2 x 10 ⁹ cpm / μg DNA). The filters are then each once 20 minutes at 65 ° C with 6 x SSC, 1 x Denhardt's solution, 0.5% SDS, 20 ug / ml denatured herring sperm DNA, then with 1 x SSC, 0.5% SDS 1 x Denhardt Solution and 0.1 x SSC, 0.05% SDS and dried at 80 ° C. The autoradiography is carried out using X-ray film and intensifying film (intensely fying screens Kodak) with an autoradiography time of 6-48 hours at -70 ° C.

* 20 x SSC (standard saline citrate) corresponds to 3 M NaCl, 1.5 M sodium citrate.

** SDS sodium dodecyl sulfate

*** 100 x Denhardt's solution corresponds to 2% Ficoll; 2% polyvinyl pyrolidone, 2% bovine serum albumin. Example 8

This example shows a simpler variant regarding sample preparation for dot blot:

1 ml serum is mixed with 350μl Proteinase K solution (3 mg / ml Proteinase K, 10 mM TRIS pH 7.5, 0.5 mM EDTA, 0.5% SDS) and 125 μl 0.5 M EDTA -30 min. incubated at 37 ° C. The solution is then diluted to 16 ml with 8 ml of 2 M TCA (pH 7.0), 3.2 ml of 2 MNH ₄ A _C , 20 μl t of RNA (10 mg / ml) and 5.3 ml of H ₂ O. the DNA is precipitated with 10 ml of isopropanol at room temperature for 30 min. The DNA is centrifuged off (15 min. At 8000rpm), the pellet washed with 2 ml of 70% ethanol and taken up in 600μl 10 mM TRIS pH 8.4 and 1 mM EDTA, extracted once with phenol, once with chloroform and precipitated again. Aliquots of the filled DNA can be used for the dot blots or for restriction analyzes.

Particle-associated DNA from stool samples is displayed in the same way. However, stool suspensions are first sterile filtered and precipitated with PEG.

Example 9

If only a relatively small amount of the N-A, N-B-associated substance is present, it has proven expedient to detect the DNA by amplification:

The detection of non-A, non-B DNA in the serum can expediently be carried out by hybridization with radioactively labeled cloned non-A, non-B DNA sample after previous specific enzymatic DNA amplification by known method (SAIKI et al., Science 230, 1350, 1985). Mix 25μl serum + 50μl NaJ (saturated solution) and incubate for 2 minutes at 37 ° C, then incubate for 10 minutes at 0 ° C. The incubate is dialyzed on a polycarbonate membrane (eg Uni Pore from BioRadLab) against TE buffer (10 mmol Tris; 1mmol EDTA) for 20 minutes. 5μl of the dialysate are removed for the specific enzymatic DNA amplification. The amplification is carried out according to a known method (SAIKI et al. 1985) with the aid of 0.5 μg oligoprimer (Paa B or C and D). The oligoprimer pairs are determined using known sequencing data

DNA synthesizers (Applied BioSystem 381). After amplification, the reaction mixture is separated electrophoretically on a 2% agarosgel, then transferred to a nylon membrane (Genofit) and mixed with a filter according to FEINBERG et al. 1983 (Annal. Biochem. 132, 6-13) hybridized with ³² P labeled cloned HNANB DNA sample. After autoradiography, positive results are identified using standards and length markers.

Example 10

Detection of DNA in tested infectious plasma derivative: Renger F. et al. published in "Deutsches Gesundheitswesen" Vol. 36, pp. 560-563 (1981) a study on a controlled hepatitis non-A, non-B epidemic triggered by the application of infectious anti-rheumatic factor D immunoglobulin preparations. The origin of these contaminated preparations could be fully clarified. After application of this anti-D preparation, 79% of 116 immunized pregnant women fell ill. This anti-D preparation (Lot I ampoules A and C) and a lot with low infectivity (Lot II ampoules B and D), which were cleaned by the same column system, were available together with control preparations (Gammavenin, Endobolin, Rhesonativ). These preparations were used together with buffer controls, hepatitis B virus-containing serum, positive controls with cloned virus DNA fragments. The detection was carried out by means of DNA amplification by primers 237-238 (originating from the 0.4 Kb EcoRI fragment). Results:

In multiple experiments carried out under different conditions, a strong signal was found in batch I (ampoules A and C) after amplification, a weak signal with good amplification yield in the

Batch II (ampoules B and D). The three control lyophilizates Gammavenin, Endobolin and Rhesonativ gave no signal. The addition of hepatitis B virus genome-specific primers to the various gamma globulin preparations also gave no indication of possible contamination with the hepatitis B genome. The controls carried out served to assess the efficiency of the amplification both with HBV-specific primers and with non-A, non-B-specific primers. The proof of the identity of the DNA in the infectious batch with the DNA from the feces of a patient with hepatitis non-A, non-B speak for the identification of a DNA implicated in hepatitis non-A, non-B.

Examination of a further 57 stool samples from patients with sporadic and post-transfusional HNANB using radioimmunoassey as described in the previous examples and using the dot blot method revealed a significant correlation between the two examination methods with regard to detectable HNANB-associated substance (RIA) and detectable DNA (dot -Blot, see example 7). The attached figures explain the invention:

Figure 1 is the sequence of the genome

Fig. 2 is an overview of the interfaces with EcoRI and the open reading frame and reading frame. Fig. 3 and Fig. 4 show the plus and minus strand of an approximately 0.3 Kb

Sequence, that is to say a partial sequence of the genome. FIG. 5 shows the open reading frame, specifically that

Reading frames 1A, 2A and 3A, and FIG. 6 shows the open reading frame for reading frames 1B,

2B and 3B.

The sequences added in the figures were sequenced using the Sanger method after cloning PUC 8 into M 13 or Bluescript vector.

The characterization of this originally present DNA shown in FIG. 1 and isolated from stool isolates shows that it is a partially double-stranded circular DNA.

The DNA shows a relationship to HBV DNA. When a cloned 0.45 Kb fragment or purified stool material was labeled with 32P and hybridized to HBV-DNA in a Southern analysis, both samples gave a signal, but about 1000 times less than with themselves. Plasmid pBR 322 and Lambda Phage gave no signal, in preliminary experiments the purified stool sample could be labeled very well with the small fragment of the E.coli polymerase without being denatured.

Stool samples treated with Klenow polymerase migrated much more slowly in an agarose gel than the untreated sample. This suggests that the DNA examined, like HBV DNA, is partially double-stranded. The results and treatment with restriction enzymes and primer extension demonstrate a circular structure of the DNA. Sequence analyzes of both DNA carried out several times

Strands gave 4998 base pairs. The sequence is shown from the 5 'to the 3' end, the numbering with 1 begins in the first nucleotide of the 2.5 Kb EcoRI fragment in the DNA strand which contains the large open reading frames (see Fig. 2). A DNA fragment of approx. 10 to 20 base pairs, not shown in the illustration, was experimentally detected and borders on the 2.5 and 1.5 Kb EcoRI fragments and therefore causes the ring closure of the linearly imaged DNA (see Fig. 2) . This fragment was detected by an amplification experiment, in which purified virus DNA was incubated with Klenow polymerase and the two synthetic primers 13 and 17, and the DNA sequence between the primers was amplified several times and, after electrophoresis, was detected by Southern analysis. Since the two primers are located at the two ends of the sequenced DNA, a fragment can only be amplified if the DNA is circular. The virus genome thus has a total length of 5,010 to a maximum of 5,050 base pairs. This result is additionally confirmed by independent Southern analysis of the genome. The restriction map of the genome is available. The order e.g. The individual EcoRI fragments are: 1.5 / 0.45 / 0.3 / 0.15 and 2.5 Kb.

With regard to special features of the sequence, it should be stated that a Tange palindromic sequence (hairpin) lies between base pairs 2,097 and 2,149 at the end of an open reading frame (item 4, Fig. 2).

There is a "CTG" box at positions 424 and 3,303. The CTG box of 3,303 also contains 2 repeats that have sequence homology with the direct repeats of the Hepadnaviridae. The open reading frames are mainly found on one strand. The other strand, like hepatitis B virus DNA, is closed except for smaller peptides. While the open DNA strand can code for proteins up to molecular weights over 40,000 without further modification, in the complementary strand wide areas of all three reading frames are closed except for 5 peptides with a smaller molecular weight of approx.6,000 (see Fig. 2 and Fig. 5 and 6).

All overlapping clones gave identical results for the same sequence with one exception, where G was found at position 2.381 in one case and A in another case. A sequencing error must be excluded.

This gives an indication of what is confirmed by further findings that deviations of a few percent, in particular 1 to 2%, generally have no influence on the function of the sequence, so that functional equivalent deviations of up to 5%, in particular up to 2% of the basic structure. The same applies to the proteins encoded by such DNAs.

In summary, the following can be said: The non-A, non-B-associated substance is characterized by the significant binding to immunoglobulins and the binding to Fab2 fragments of purified IgGs, by binding to non-collagen-binding fibronectin cleavage products and by the infectiousness towards human cell culture lines, which can be represented morphologically by virus-typical changes of the same and molecular genetically by the detection of a specifically hybridizing, gel electrophoretically migrating DNA with an apparent size of 3.2 KB (uncut and under native conditions) within these cell cultures. The in the infected cells as well as in the serum of non-A,

DNA detectable in non-B hepatitis patients hybridizes with the approx. 5 KB DNA isolated from non-A, non-B substance or the cloned DNA produced from this material.

The mth sequence of approx. 5,000 base pairs according to FIG. 1 and partial sequence of approx. 300 base pairs according to FIGS. 3 and 4 of the cloned DNA were determined and with known human DNA sequences, phage DNA sequences, plasmid DNA sequences and known published virus DNA sequences compared. According to this data, they do not correspond to any sequence previously described. After the open reading frame of the sequence, conclusions can be drawn about the encoded and expressed virus-specific proteins. So you can make the hydrophilic and hydrophobic

Identify regions within the peptides and thus the production of synthetic peptides from the possible antigenic epitopes in the hydrophilic regions is possible.

The DNA found, in particular the genes located on this DNA, can be used for insertion into corresponding expression vectors, such as cells and bacteria (for example E. coli and yeasts, such as Syccharomyces cereviciae and cell cultures), and thus for the production of virus antigens. This enables diagnostics and the production of immune reagents and vaccines. In diagnostics, the examination for infectivity (blood test) and the diagnosis of an acute, chronic or past infection must be mentioned, antigens produced in cell cultures and the corresponding proteins synthesized by this virus DNA in vivo and in vitro can be used to create immunological Diagnostics are used. The DNA sequence can be used to identify potential viral proteins and their synthetic production, ie the production of synthetic antigenic peptides, just like the DNA or partial DNA sequences for the production of synthetic DNA or RNA or DNA or RNA fragments and for the

Use them as probes or primers for diagnostics. Finally, you can use the DNA or the created DNA sequence for the production of synthetic viruses (complete DNA synthesis) and for the insertion of synthetic DNA or DNA fragments into the corresponding ones

Use vectors to get virus expression products.

Claims

1. NANB hepatitis-associated DNA, containing above all the DNA according to FIG. 1 and functional equivalents and partial sequences thereof.

2. NANB hepatitis-associated DNA according to claim 1, characterized in that it shows at most 5%, in particular at most 2%, deviation from the structure and / or chain length of the DNA according to FIG. 1.

3. NANB hepatitis-associated DNA according to claim 1 or 2, characterized in that it is partially double-stranded circular and isolated from a NANB hepatitis-associated particle or virus.

4. DNA partial sequence according to claim 1 -3, characterized in that it Fig. 3 or 4 with a maximum

5%, preferably a maximum of 2%, corresponds to the deviation.

5. Proteins, characterized in that they are encoded by a DNA according to claim 1 to 4 or correspond to proteins encoded in this way.

6. Proteins according to claim 5, characterized in that they correspond to the sequences of the open reading frame

5 and 6 correspond.

7. A process for the preparation of the NANB-associated DNAs according to claims 1-4 (and the proteins according to claims 5 and 6) from stool, tissue, body fluids or virus cultures, characterized in that the starting material, if necessary after prior sterile filtration and precipitation with PEG in the case of stool suspensions, incubated with DNase and, if necessary, RNase for digestion, then a density gradient, in particular CsCl, d = 1.3, is applied, whereupon dialysis, digestion with Proteinase K, phenol extraction, ethanol precipitation and, if necessary, extraction and renewed precipitation and isolation as well as, if necessary, cloning and, if necessary, expressing in appropriate vectors.

8. Use of the DNAs according to claims 1 to 4 as DNA probes for diagnosis, in particular according to classic hybridization methods, or for expression in suitable vectors.

9. Use of the DNAs according to claim 1 to 4 for the synthesis of proteins for the production of immunological reagents for the detection of NANB hepatitis and for the production of vaccines.

10. Use of the DNAs according to claim 1 to 4 or the genes located on these DNAs or the corresponding DNA sequences for the production of synthetic viruses and for inserting the natural or synthetic DNAs or DNA fragments into corresponding ones. Vectors for the formation of virus expression products and for the production of virus antigens.